Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.52 |
| ▸ | EIF4H | Q15056 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5450935 | 0.98 | NSD2 (0.54) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| SCHEMBL227218 | 0.87 | NCF1 (0.47) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL229271 | 0.85 | NCF1 (0.46) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| SCHEMBL27719184 | 0.85 | NSD2 (0.58) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| SCHEMBL29550511 | 0.83 | NSD2 (0.60) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| SCHEMBL335469 | 0.83 | NSD2 (0.60) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| SCHEMBL5680469 | 0.81 | NSD2 (0.59) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| SCHEMBL5680479 | 0.81 | NSD2 (0.59) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| SCHEMBL1804352 | 0.81 | PARP1 (0.56) | NSD2PABPC1EIF4HALDH1A1MEN1 | |
| SCHEMBL4520228 | 0.81 | NSD2 (0.55) | NSD2PABPC1EIF4HALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574175-B | Quinoline compound, preparation method and application thereof | 南京长澳医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2021057190-A1 | QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海阳帆医药科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574175-A | Quinoline compound, preparation method and application thereof | 上海阳帆医药科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| CN-102442970-A | Thiazole compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| EP-2285800-B1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-0171037-B1 | 3-CARBONYL-1-AMINOALKYL-1H-INDOLES USEFUL AS ANALGESICS AND PREPARATION THEREOF | STERLING WINTHROP INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| US-5013732-A | Analgesics | STERLING DRUG INC. (US) | 1991-05-07 | — | — | US | disclosed |
| US-4978664-A | Analgesic, anti-rheumatic, and anti-inflammatory agent | STERLING DRUG INC. (US) | 1990-12-18 | — | — | US | disclosed |
| US-4885295-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | STERLING DRUG INC. (US) | 1989-12-05 | — | — | US | disclosed |
| US-RE32761-E | ANALGESICS, ANTIRHEUMATIC AND ANTIINFLAMMATORY AGENT | STERLING DRUG INC. (US) | 1988-10-04 | — | — | US | disclosed |
| US-4634776-A | ANALGESIC, ANTIRHEUMATIC, ANTIINFLAMMATORY | STERLING DRUG, INC. (US) | 1987-01-06 | — | — | US | disclosed |
| US-4581354-A | ANALGESICS;ANTI-RHEUMATIC AND ANTI-INFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1986-04-08 | — | — | US | disclosed |
| EP-0171037-A2 | 3-Carbonyl-1-aminoalkyl-1H-indoles useful as analgesics and preparation thereof | STERLING WINTHROP INC. (US) | 1986-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | NSD2 790/4885PABPC1 4168/4885EIF4H 2999/4885 |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | NSD2 4579/4885PABPC1 4077/4885EIF4H 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.